To examine the impact of endoscopic sinus surgery (ESS) on olfactory impairment in patients with chronic rhinosinusitis (CRS) over intermediate and long-term follow-up. We hypothesized that patients with mild olfactory dysfunction (hyposmia) would benefit from ESS, whereas patients with severe olfactory dysfunction (anosmia) would not. STUDY DESIGN: Prospective, multi-institutional cohort study. SUBJECTS AND METHODS: A total of 111 patients presenting for ESS for treatment of CRS were examined preoperatively, and at 6 and 12 months postoperatively. Demographic, comorbidity, and Smell Identification Test (SIT) data were collected at each time point. Univariate and multivariate analyses were performed. RESULTS: The prevalence of gender-adjusted olfactory dysfunction prior to surgery was 67.5 percent. Surprisingly, hyposmic patients did not significantly improve after surgery. In contrast, patients with anosmia significantly improved after ESS (baseline, 6-month SIT scores: 9.7 Ϯ 2.0, 21.3 Ϯ 11.2; P ϭ 0.001). Improvement was sustained at 12-month follow-up (21.7 Ϯ 10.7; P ϭ 0.001). Multivariate linear regression analysis showed that baseline olfactory category and nasal polyposis were significantly associated with improvement in postoperative olfactory function (P ϭ 0.035, P ϭ 0.002). CONCLUSION: Contrary to our hypotheses, patients with severe olfactory dysfunction significantly improved after ESS and sustained improvement over time, whereas patients with mild olfactory dysfunction did not.
D ecreased sense of smell is a common problem affecting approximately 61 to 69 percent of patients with chronic rhinosinusitis (CRS), and is one of the four signs and symptoms used to diagnose CRS. 1 Olfactory impairment negatively impacts patients' quality of life and ability to function safely in day-to-day life. 2 Despite being a common complaint in the setting of sinusitis, relatively little objective data are available regarding the impact of endoscopic sinus surgery (ESS) on olfactory function.
Much of the olfactory literature is based on subjective reports of olfactory function, which do not accurately assess objective olfactory impairment. 3, 4 A small number of prospective studies with objective olfactory outcomes have been performed with mixed results. 3, [5] [6] [7] [8] [9] [10] The use of different olfactory measures and definitions of improvement have added confusion to the interpretation of results. Additionally, the majority of studies report short-term follow-up of 6 months or less and do not account for long-term changes that may occur in the postoperative period.
In this multi-institutional, prospective cohort study, the impact of ESS on olfactory impairment in patients with CRS was objectively examined over 6-month and 12-month follow-up. We hypothesized that patients with mild olfactory impairment (hyposmia) would benefit from ESS but patients with severe olfactory impairment (anosmia) would not.
MATERIALS AND METHODS

Study Population and Data Collection
Study subjects were recruited from three tertiary care centers over a 3-year period as part of a multi-institutional prospective cohort study. All patients had a diagnosis of CRS based on the Rhinosinusitis Task Force criteria and endorsed by the American Academy of Otolaryngology -Head and Neck Surgery. 11 Adult (Ն18 years old) patients were enrolled at the time they had failed maximum medical management and had elected to undergo ESS. Maximum medical management was defined as a prolonged course of broad-spectrum or culture-directed antibiotics Ն4 weeks and a trial of topical nasal corticosteroid spray. 12, 13 Patients with immunodeficiency (n ϭ 5), autoimmune disease (n ϭ 8), and/or cystic fibrosis (n ϭ 12) were excluded.
Demographic and clinical data were collected, including age, gender, current tobacco use, history of prior sinus surgery, nasal polyposis, asthma, allergic rhinitis confirmed by allergy testing, acetylsalicylic acid (ASA) intolerance, and topical and systemic corticosteroid use. Patients on systemic corticosteroids were being treated for significant comorbid disease, including poorly controlled asthma and severe ASA intolerance. Preoperative CT scan and preoperative endoscopy examination were scored with the Lund-MacKay and Lund-Kennedy scoring systems. 14, 15 Olfactory function was measured with the Smell Identification Test (SIT). Clinicians scoring the CT scan and endoscopy examination were blinded to the olfactory test results. The extent of surgery was tailored to the patient's disease process as defined by signs, symptoms, CT scan, and clinical judgment. Patients were followed for 1 year postoperatively. Patients underwent olfactory testing and nasal endoscopy examination at 6-and 12-month postoperative follow-up. A total of 111 patients with 1-year postoperative follow-up were available for analysis, including 34 patients from Oregon Health and Science University, 38 patients from the Medical College of Wisconsin, and 39 patients from Stanford University. All study protocols and informed consent were collected and approved by the institutional review boards at each study site.
Measurement of Olfactory Function
The SIT from Sensonics, Inc, an objective measure of olfactory function, was administered to patients. 16 The SIT is a validated 40-question forced-choice test (total score: 0-40) with high test-retest reliability (r Ͼ 0.90) and is highly correlated with more sophisticated measures of olfactory dysfunction (r Ͼ 0.80). 17, 18 Absolute SIT scores were categorized into olfactory severity categories on the basis of robust gender-adjusted, normative data (normosmics: men with SIT scores 34-40 and women with SIT scores 35-40; microsmics/hyposmics: men with SIT scores 19-33 and women with SIT scores 19-34; anosmics: men and women with SIT scores 6-18). 16 Patients with SIT scores of zero to five were categorized as malingering and removed from the analyses (n ϭ 4). Age was not part of the classification system, and was included as a covariate and adjusted for in the analyses.
Statistical Analyses
All statistical analyses were performed with SPSS ver-sion16.0 statistical software (SPSS Inc, Chicago, IL). Baseline demographics, clinical factors, and changes in mean 12-month postoperative SIT scores were compared across preoperative olfactory diagnostic categories by means of the Kruskal-Wallis test and 2 analyses where appropriate. A two-tailed P value Յ 0.05 was considered statistically significant. A subset of patients (n ϭ 80) also had 6-month postoperative data available for analysis. There was no difference in baseline characteristics of patients with and without 6-month postoperative follow-up. The Wilcoxon signed rank test was used to examine differences in SIT scores at different time points. Means and SDs were reported. Olfactory outcomes were stratified by clinical cofactors to assess for effect modification.
The percentage of patients with an absolute change in SIT score of Ն4 points was also examined; this corre-sponded to an individual test-retest change in SIT score outside the 95 percent confidence interval. 19 Significant differences in proportions were tested by 2 analysis.
Multivariate linear regression modeling was performed to adjust for all significant cofactors associated with improvement in olfactory function. The main outcome of interest was 12-month postoperative change (postoperative minus preoperative) in SIT score. Preliminary models included demographic and patient variables with univariate significance at the P Յ 0.25 level. Interactions between variables were examined; an interaction variable was retained in the preliminary model if it was significant at the P Յ 0.10 level. The final model was chosen by using manual forward selection and backwards elimination stepwise procedures based on P ϭ 0.05 and P ϭ 0.10 levels of significance. Baseline differences in olfactory function were accounted for by retaining the preoperative SIT score in the final model. Effect modification between baseline olfactory category and nasal polyposis was noted, and retained in the model. Diagnostic analyses were performed to verify linearity assumptions and model accuracy.
RESULTS
Demographic Data and Baseline Characteristics of Patients with Olfactory Impairment
Of the 111 patients with 12-month postoperative follow-up in this study, 32.4 percent (n ϭ 36) were normosmic, 50.5 percent (n ϭ 56) were hyposmic, and 17.1 percent (n ϭ 19) were anosmic. Baseline demographic characteristics, clinical characteristics, and comorbidity data are described in Table 1 . On average, patients with olfactory impairment were older (P ϭ 0.028); more likely to have nasal polyposis (P Ͻ 0.001), asthma (P ϭ 0.004), and/or aspirin intolerance (P ϭ 0.012); and had higher (worse) CT scores (P Ͻ 0.001) and endoscopy scores (P ϭ 0.006).
Postoperative Results by Olfactory Status
SIT scores in anosmic patients significantly improved after sinus surgery at 6-month follow-up (preoperative mean score: 9.7 (Ϯ2.0); 6-month postoperative mean score: 21.3 (Ϯ11.2); P ϭ 0.001), whereas they did not improve in hyposmic patients (28.8 Ϯ 4.5 to 30.0 Ϯ 5.5; P ϭ 0.113) ( Fig 1) . Anosmic patients sustained improvement at 12month follow-up (mean SIT score 21.7 Ϯ 10.7; P ϭ 0.001). There was no change in hyposmics' mean SIT score at 12-month follow-up (29.5 Ϯ 6.2; P ϭ 0.656). In normosmic patients, there was no difference between preoperative and 6-month postoperative scores (35.8 Ϯ 1.3 vs 34.3 Ϯ 5.3, P ϭ 0.273). Furthermore, there was no difference between 6-and 12-month postoperative scores (34.3 Ϯ 5.3 vs 34.5 Ϯ 3.8; P ϭ 0.834).
When change was defined as Ն4 point difference between the preoperative SIT score and 12-month postopera-tive SIT score, olfaction improved in 73.7 percent of anosmic patients, showed no change in 15.8 percent, and worsened in 10.5 percent. In contrast, only 26.8 percent of hyposmic patients improved after surgery, 53.6 percent showed no change, and 19.6 percent worsened. Among normosmic patients, 88.9 percent reported no change after surgery, whereas 11.1 percent reported worse olfaction. The proportion of patients with anosmia who improved after surgery was significantly greater than the proportion of patients with hyposmia who improved after surgery (P Ͻ 0.001). No preoperative normosmic patient was anosmic at 12-month postoperative follow-up.
Role of Nasal Polyposis in Postoperative Improvement
An interaction between nasal polyposis and olfactory function was identified (P ϭ 0.007) ( Fig 2) . In patients with anosmia, those with nasal polyposis had similar preoperative SIT scores compared with those patients without nasal polyposis (9.4 Ϯ 1.9 vs 10.8 Ϯ 1.9; P ϭ 0.224). Postoperatively, anosmic patients with nasal polyposis showed significant improvement in 12-month olfactory change score (13.9 Ϯ 10.2; P ϭ 0.002), whereas nonpolyp patients did not (6.6 Ϯ 12.8; P ϭ 0.461). SIT scores did not differ in normosmic and hyposmic patients by nasal polyp status. 
Topical and Systemic Corticosteroid Use and Olfaction
Sixty-three percent of patients (n ϭ 70) were on topical corticosteroids prior to surgery, and 78.4 percent were using topical corticosteroids 1 year after surgery (n ϭ 87). The preoperative mean SIT score was not statistically different between those taking topical corticosteroids (27.6 Ϯ 9.4) and those not taking topical corticosteroids (28.1 Ϯ 9.6; P ϭ 0.800). The mean SIT scores were not statistically different in each olfactory group by topical corticosteroid use preoperatively or at 1-year follow-up (Table 2) . Twentythree percent of patients (n ϭ 26) were on systemic corticosteroids prior to surgery, and 13.5 percent were taking systemic corticosteroids 1 year after surgery (n ϭ 15). The preoperative mean SIT score was not statistically different between those taking systemic corticosteroids (25.6 Ϯ 10.1) and those not taking systemic corticosteroids (28.4 Ϯ 9.2; P ϭ 0.191). The mean SIT scores were not statistically different in each olfactory group by systemic corticosteroid use preoperatively or at 1-year follow-up (Table 3 ).
Multivariate Linear Regression Analysis
Finally, a multivariate linear regression analysis was performed with 12-month postoperative change in absolute SIT score as the primary outcome of interest. Baseline olfactory status (namely, anosmia) (P ϭ 0.035) and nasal polyposis (P ϭ 0.002) were both significant predictors of improve-ment in SIT score at 12-month postoperative follow-up. Furthermore, an interaction, or effect modification, between baseline olfactory status and nasal polyposis was noted both graphically ( Fig 2) and statistically in the multivariate linear regression analysis and remained in the final model (P ϭ 0.007). Other variables, including age, gender, pre-and postoperative topical and systemic corticosteroid use, asthma, allergic rhinitis confirmed by allergy testing, ASA intolerance, current tobacco use, history of prior sinus surgery, preoperative CT scan, and preoperative endoscopy score were not significant variables in the model (all P Ն 0.592). Thirtythree percent of the variability in the change in olfactory score was explained by the following model
Y ϭ 12 month change in sit score ␤ 0 ϭ constant X 1 ϭ baseline olfactory category X 2 ϭ nasal polyposis ε ϭ error value
DISCUSSION
In this multi-institutional prospective cohort study, we found that, contrary to our hypotheses, olfactory impairment improved in patients with anosmia after ESS but not in patients with hyposmia. This improvement in anosmic patients' objective olfactory scores was sustained at 1-year follow-up. Both baseline olfactory status and nasal polyposis were significant predictors of improvement in 12month postoperative olfactory scores. Finally, no patient who was normosmic prior to surgery was anosmic at 1-year follow-up. Some believe that nasal polyposis patients find only brief and temporary resolution of olfactory impairment. 20 In contrast, we found significant improvement in olfactory scores in anosmic patients with nasal polyposis 6 months after surgery; this improvement was sustained at 12-month follow-up. In fact, nasal polyposis was a significant predictor of better postoperative olfactory outcomes at 12-month fol-low-up. These findings are consistent with other studies in the literature. Pade and Hummel 7 found nasal polyposis to be the most important factor in determining olfactory improvement 4 months after ESS. Minovi et al 6 found patients with nasal polyposis had a higher success rate of olfactory improvement at 6-month follow-up than other patients. Although patients with nasal polyposis are at risk for recurrent disease, the removal of mechanical obstruction from the olfactory cleft and consequent increase in intranasal volume likely improve olfactory function over the 1-year postoperative period.
In contrast to our initial hypothesis, we found that anosmic patients improved after ESS, whereas hyposmic patients did not. We had suspected that hyposmics had anatomical obstruction secondary to their disease that would benefit from surgical removal, whereas anosmic patients would have underlying multifactorial olfactory impairment, including both physical obstruction of the olfactory cleft and direct inflammation of the neuroepithelium that would not benefit from surgical treatment.
Given our findings that anosmics improved whereas hyposmics did not, we hypothesize that this difference in olfactory outcomes occurred, at least in part, as a result of nasal polyposis causing anosmia. Because patients with nasal polyps and anosmia likely have complete obstruction of the olfactory cleft, surgical resection of this local inflammatory process improved olfaction. In fact, anosmic patients with nasal polyposis improved significantly more than patients without nasal polyposis. Interestingly, this interaction between nasal polyposis and other variables in CRS and olfactory outcomes studies has been noted by us and others in prior studies. 6, 21 The potential for nasal polyposis to interact with other variables should be addressed in the analyses of outcomes data and should be investigated in future studies.
Several pertinent negative findings were also identified. Age, gender, allergy status, ASA intolerance, and a history of prior sinus surgery were not significant predictors of postoperative olfactory improvement. Some of these findings have been noted in short-term olfactory outcome studies. [5] [6] [7] ASA intolerance has been found to be a significant predictor in some studies 6 but not others. 7 We suspect that ASA intolerance was not a significant predictor because it was accounted for in the regression analysis by nasal polyposis. Smoking is a known risk factor for olfactory impairment, but it was not a significant predictor of poor olfactory outcomes. Smoking was an uncommon comorbidity in this cohort (n ϭ 5) and will likely require a larger sample size to better determine its relationship to olfactory outcomes.
Some studies suggest that use of corticosteroids improves olfaction in patients with sinus disease. 22 Reflecting real-life conditions of CRS disease management, a subset of patients took topical and/or systemic steroids to help manage underlying chronic inflammation of the nasal cavity and sinuses. Rather than eliminating them from the data set, we accounted for these patients in the analyses. Interestingly, there was no difference in the olfactory scores of patients on topical or systemic corticosteroids, nor was topical or systemic corticosteroid use a predictor of ol- factory improvement at 1-year follow-up. Importantly, no preoperative normosmic patient became anosmic as a consequence of surgery. A 1 percent risk of anosmia from nasal surgery is frequently quoted in the literature. 5 However, it is important to note that the patient in the referenced study underwent a septoplasty under local anesthetic, not ESS. Although patients should be counseled preoperatively that a hypothetical risk of iatrogenic anosmia after ESS exists, it appears to be low (less than 1%) in the hands of experienced surgeons. Preoperative CT and endoscopy scores were significantly worse in patients with olfactory impairment. However, neither measure predicted postoperative olfactory improvement; it is likely these measures were accounted for by patients' nasal polyposis status in the multivariate linear regression analysis. By adjusting for this potential confounder in the model, we observed that nasal polyposis, not CT score or endoscopy score, predicted who had improved olfactory function after surgery.
Olfactory outcomes following ESS for CRS have been difficult to interpret for several reasons. First, many studies report subjective olfactory results, which do not necessarily correlate with objective olfactory assessment. 4 In fact, patients' self-reported assessment of olfactory dysfunction has poor sensitivity (40%) and specificity (30%) for determining objective olfactory impairment. 3 Consequently, olfactory outcomes studies require the use of objective olfactory measures. Second, several older studies were performed retrospectively, leading to several study limitations and potential biases. More recently, more prospective olfactory outcome studies have been performed. However, the heterogeneity of olfactory tests, outcomes, and postoperative follow-up have added additional challenges to the comparison of results from various studies, making the interpretation of data difficult, and leading to different outcomes (Table 4 ). 3, [5] [6] [7] [8] [9] [10] 18, [23] [24] [25] Several different types of objective olfactory measures including odor discrimination, threshold, and/or identification testing have been reported in the literature. Different definitions of improvement including a minimum change, mean change, and median change in olfactory scores have been reported. 5, [7] [8] [9] [10] 19 Finally, many prospective studies are limited by shortterm (Յ6 month) follow-up. Long-term follow-up is important for several reasons. Patients assessed within the first couple of months after surgery may still be healing from surgery. Edema and granulation tissue may interfere with results and lead to negative studies. Conversely, patients with initial recovery and significant improvement in the early postoperative period may later suffer from scar formation, recurrence of disease, and new polyp formation in the region of the olfactory cleft, which are not captured in short-term data.
In this study, we prospectively evaluate the olfactory outcomes of ESS using an objective olfactory measure, reporting both the means and proportion of patients with improvement, and using intermediate and long-term olfactory outcomes to examine both short-term trends and long-term consequences of ESS. Our findings regarding 1-year postoperative improvement are consistent with the limited number of other studies in the literature with at least 1-year follow-up in which patients' postoperative olfactory function improved but did not return to normal. 9, 10 Our study size may have been a limitation in that we were unable to detect a difference in patients with uncommon comorbidities, such as smoking. However, we had appropriate power to detect olfactory improvement, differences in subgroups of patients, and the ability to adjust for potential confounders, such as corticosteroid use, in our analysis. Furthermore, our 12-month findings are consistent with the few other published reports in the literature.
CONCLUSION
Olfactory impairment is common in patients with CRS. In this multi-institutional prospective cohort study, olfactory dysfunction improved in patients with anosmia after ESS and was sustained at 1-year follow-up. In contrast, patients with hyposmia did not improve after surgery. Although anosmics experienced significant improvement, olfactory function did not return to normal in most patients. No normosmic became anosmic after surgery. Olfactory impairment is an important patient safety and quality-of-life issue for patients with CRS and one that requires continued research.
